- Zacks
TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?
Teva's reasonable valuation, an improving pipeline and the prospect of growth in sales and profits are good enough reasons for those who own the stock to stay invested.
- Reuters
Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial
Baltimore said on Tuesday that it has settled with Walgreens over claims that the pharmacy operator fueled opioid addiction in the Maryland city, the latest in a series of settlements totaling $402.5 million ahead of a trial scheduled to begin next week. The announcement came a day after the city reached an $80 million settlement over opioids with drugmaker Teva Pharmaceutical. Baltimore did not disclose the terms of its settlement with Walgreens, but the cumulative settlement amount implies that it was also $80 million.
- Benzinga
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
JP Morgan notes that while there’s a resurgence of interest and excitement in new product launches within the specialty group, including branded and complex generics/biosimilars, investors should be discerning about these opportunities. The group’s core fundamentals have strengthened, buoyed by a more stable environment for generic and established brand pricing, which helps mitigate the usual erosion in base business prices. However, growth in the overall sector remains modest, with most compani
